Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,201 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Capecitabine and paclitaxel combination chemotherapy for inoperable or recurrent breast cancer: a phase I dose-finding study by the Kinki Breast Cancer Study Group.
Masuda N, Taguchi T, Nakayama T, Shiba E, Watatani M, Kurebayashi J, Takatsuka Y, Sakamoto J, Noguchi S; Kinki Breast Cancer Study Group (KBCSG). Masuda N, et al. Cancer Chemother Pharmacol. 2008 May;61(6):989-95. doi: 10.1007/s00280-007-0555-z. Epub 2007 Jul 20. Cancer Chemother Pharmacol. 2008. PMID: 17641893 Clinical Trial.
Phase II study of preoperative sequential FEC and docetaxel predicts of pathological response and disease free survival.
Toi M, Nakamura S, Kuroi K, Iwata H, Ohno S, Masuda N, Kusama M, Yamazaki K, Hisamatsu K, Sato Y, Kashiwaba M, Kaise H, Kurosumi M, Tsuda H, Akiyama F, Ohashi Y, Takatsuka Y; Japan Breast Cancer Research Group (JBCRG). Toi M, et al. Among authors: masuda n. Breast Cancer Res Treat. 2008 Aug;110(3):531-9. doi: 10.1007/s10549-007-9744-z. Epub 2007 Sep 19. Breast Cancer Res Treat. 2008. PMID: 17879158 Clinical Trial.
Phase II study of capecitabine and trastuzumab combination chemotherapy in patients with HER2 overexpressing metastatic breast cancers resistant to both anthracyclines and taxanes.
Ishida T, Kiba T, Takeda M, Matsuyama K, Teramukai S, Ishiwata R, Masuda N, Takatsuka Y, Noguchi S, Ishioka C, Fukushima M, Ohuchi N. Ishida T, et al. Among authors: masuda n. Cancer Chemother Pharmacol. 2009 Jul;64(2):361-9. doi: 10.1007/s00280-008-0882-8. Epub 2008 Dec 12. Cancer Chemother Pharmacol. 2009. PMID: 19082596 Free PMC article. Clinical Trial.
Prospective assessment of chemotherapy-induced peripheral neuropathy due to weekly paclitaxel in patients with advanced or metastatic breast cancer (CSP-HOR 02 study).
Kuroi K, Shimozuma K, Ohashi Y, Hisamatsu K, Masuda N, Takeuchi A, Aranishi T, Morita S, Ohsumi S, Hausheer FH. Kuroi K, et al. Among authors: masuda n. Support Care Cancer. 2009 Aug;17(8):1071-80. doi: 10.1007/s00520-008-0550-x. Epub 2008 Dec 17. Support Care Cancer. 2009. PMID: 19089463
Predictive factors for anthracycline-based chemotherapy for human breast cancer.
Miyoshi Y, Kurosumi M, Kurebayashi J, Matsuura N, Takahashi M, Tokunaga E, Egawa C, Masuda N, Kono S, Morimoto K, Kim SJ, Okishiro M, Yanagisawa T, Ueda S, Taguchi T, Tamaki Y, Noguchi S. Miyoshi Y, et al. Among authors: masuda n. Breast Cancer. 2010 Apr;17(2):103-9. doi: 10.1007/s12282-009-0152-6. Epub 2009 Aug 6. Breast Cancer. 2010. PMID: 19657712 Review.
1,201 results